Category Archives: Cancer and neoplasms

Park HS, Lloyd S, Decker RH, Wilson LD, Yu JB. Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance. Curr Probl Cancer. 2012;36(4):183–90. Article  PubMed  Google Scholar  Malmgren JA, Calip GS, Atwood MK, Mayer M, Kaplan HG. Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and […]

Introduction Postmastectomy pain syndrome is a debilitating form of chronic persistent postsurgical pain (PPSP) with neuropathic characteristics. Patients often describe this pain as burning, stabbing, or pulling sensations localized in the anterior thorax, axilla, or upper medial arm, generally ensuing after mastectomy, lumpectomy, or other breast-related surgical procedures.1–3 Several authors have advocated for a broader […]

Specialty

Specialty

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma —  Phase 1b/2 Trial Will Investigate Mezigdomide in Combination with Selinexor  in Patients with Relapsed/Refractory Multiple Myeloma Progressing after T-cell Immunotherapies – — Expected to be Initiated 1H 2024 […]

Specialty

Patients with myeloproliferative neoplasms (MPNs) — blood cancers that cause the bone marrow to overproducer red or white blood cells or platelets, including polycythemia vera, essential thrombocythemia and myelofibrosis — can experience early satiety, or a sense of fullness soon after they start eating, due the disease’s impact on their body. “Part of the reason it happens […]

Abstract Observational studies have reported a correlation between Helicobacter pylori infection and colorectal cancer (CRC); however, the underlying cause has remained unclear. This research was aimed at determining whether there is a correlation between H. pylori infection and CRC by measuring the prevalence of H. pylori CagA antibodies and VacA antibodies. Using data from many […]

LONDON–(BUSINESS WIRE)– GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia. Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 […]

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Pemigatinib overview Pemigatinib (Pemazyre) is acts as an anti neoplastic agent. […]